Jeff White is a partner in the Antitrust/Competition practice of Weil, Gotshal & Manges LLP. Mr. White provides counsel for all aspects of antitrust law, including mergers, acquisitions, joint ventures, as well as government investigations, private litigation, and general counseling. He has experience across a wide range of industries, including information technology and software, telecommunications, internet, healthcare and pharmaceuticals, medical devices, oil and gas, energy and power, chemicals, financial services, automotive, and retail. Mr. White obtained his JD from the University of Virginia School of Law in 2004 where he served as a member on both the Virginia Law Review and Virginia Tax Review. He earned his BS in Commerce, with distinction, from the University of Virginia McIntire School of Commerce in 2001. Mr. White is admitted to the bars of the State of New York and the District of Columbia. He also is an active member in the American Bar Association, serving as Vice Chair of the Antitrust Section’s Health Care and Pharmaceuticals Committee and as an Executive Editor for the Committee’s quarterly publication, the Antitrust Health Care Chronicle.
420
FTC Applies its Merger Remedy Best Practices and Announces a New Divestiture Principle in Recent Pharmaceutical Enforcement Action* On April 27, 2018, the Federal Trade Commission (“FTC”) announced a proposed consent agreement with Amneal Pharmaceuticals LLC (“Amneal”) and Impax Laboratories, Inc. (...)
501
On September 15, 2008, the FTC announced that it challenged a manufacturing, distribution, and supply agreement between Fresenius Medical Care Ag & Co. KGaA (Fresenius) and Daiichi Sankyo Company, Ltd. (“Daiichi”) based on allegations that the proposed transaction would violate U.S. (...)
332
United States of America, Mergers, Competition Authority, Consent Order, Access to information, Anticompetitive effect, Barriers to entry, Coordinated effects, Geographic market, Prices increase, Unilateral effects, Vertical restrictions, Other services, National provision prohibiting (...)
417
The explosion of private-equity financing in global capital markets resulted in a record year for 2006. In that year alone, private- equity firms raised more than $400 billion, established over 600 new funds, and spent roughly $737 billion globally on buyouts. In addition, the wide- spread (...)
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 149
New York, NY, 10001, USA
563 Chiswick High Road
W4 3AY London, UK